ImpediMed

ImpediMed Treasury Stock

The Treasury Stock of ImpediMed (IPD.AX) as of Nov 12, 2026 is 389.28 M AUD. In the previous year, Treasury Stock was 9.23 M AUD — a change of 4,116.67% (higher).

Treasury Stock

389.28 MAUD

YoY

4,116.67%

Last updated:

Treasury Stock of ImpediMed is 2026 389.28 M AUD. Treasury Stock of ImpediMed was 2025 9.23 M AUD. It decreases by 4,116.67% higher compared to the previous year.

The ImpediMed Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2019
24.78 M AUD
Jan 1, 2020
26.86 M AUD
Jan 1, 2021
1.00 AUD
Jan 1, 2022
34.13 M AUD
Jan 1, 2023
8.05 M AUD
Jan 1, 2024
8.32 M AUD
Jan 1, 2025
9.23 M AUD
Jan 1, 2026
389.28 M AUD
The ImpediMed Treasury Stock history
YEARTreasury StockYoY
389.28 MAUD+4,116.67%
9.23 MAUD+10.96%
8.32 MAUD+3.41%
8.05 MAUD-76.42%
34.13 MAUD+3.41 B%
1.00AUD-100.00%
26.86 MAUD+8.41%
24.78 MAUD+2.48 B%
1.00AUD-100.00%
16.53 MAUD+1.65 B%
1.00AUD-100.00%
3.49 MAUD-39.89%
5.81 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Treasury Stock of ImpediMed is 389.28 M AUD in 2026.

Treasury Stock of ImpediMed changed from 9.23 M AUD to 389.28 M AUD, representing a 4,116.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ImpediMed

All Key Metrics — ImpediMed